Composition that comprises at least one oxime and its use in therapeutics

Abstract

This invention relates to a medication, a pharmaceutical composition. and method for the treatment of respiratory poisoning in animals and humans caused by organophosphorus compounds, whereby said medication and said pharmaceutical composition comprise at least one oxime and one blocker of organic cation transporters (OCT).

1 . Method for the treatment of respiratory poisoning in animals and humans caused by organophosphorus compounds, comprising the blocking of organic cation transporters at the renal level (OCT) and the administration of an effective amount of at least one oxime. 
   
   
       2 . Method according to  claim 1 , in which the blocking of the OCT is due to a renal insufficiency or has been caused in particular by administration of a chemical agent. 
   
   
       3 . Method according to  claim 1 , according to which the poisoning has been caused by active pesticide substances selected from the group that comprises paraoxon, dichlorvos, chlorpyrifos, fenthion, dimethoate, and mixtures thereof. 
   
   
       4 . Method according to  claim 2 , according to which the administration of the oxime and the agent that blocks the OCT is sequential, simultaneous or successive; preferably the administration of the agent that blocks the OCT is done before the administration of the oxime. 
   
   
       5 . Method according to  claim 4 , according to which the administration of the blocking agent is done approximately 60 minutes, preferably approximately 30 minutes, and more preferably still approximately 15 minutes before the administration of the oxime. 
   
   
       6 . Method according to  claim 1 , according to which the administration is oral or parenteral. 
   
   
       7 . Method according to  claim 2 , according to which the agent that blocks the OCT is selected from the group that comprises tetraethylammonium (TEA), thiamine, and mixtures thereof. 
   
   
       8 . Method according to  claim 7 , characterized by the fact that the oxime is pralidoxime or one of its pharmaceutically acceptable salts, such as methyl sulfate, and the agent that blocks the OCT is tetraethylammonium. 
   
   
       9 . Medication that comprises at least one oxime and at least one agent that blocks the OCT as active ingredients. 
   
   
       10 . Pharmaceutical composition that comprises at least one oxime and at least one agent that blocks the OCT as active ingredients as well as at least one pharmaceutically acceptable vehicle. 
   
   
       11 . Pharmaceutical composition according to  claim 10 , for sequential, simultaneous or successive administration that comprises at least one oxime, optionally with at least a first vehicle, and at least one blocker of organic cation transporters (OCT), optionally with at least a second vehicle, whereby the first vehicle can be identical to the second vehicle. 
   
   
       12 . Medication according to  claim 9 , where the agent that blocks the OCT is selected from the group that comprises tetraethylammonium (TEA), thiamine, and mixtures thereof. 
   
   
       13 . Medication according to  claim 9 , where the oxime is pralidoxime or one of its pharmaceutically acceptable salts, such as methyl sulfate, and the agent that blocks the OCT is tetraethylammonium (TEA). 
   
   
       14 . Method according to  claim 2 , according to which the poisoning has been caused by active pesticide substances selected from the group that comprises paraoxon, dichlorvos, chlorpyrifos, fenthion, dimethoate, and mixtures thereof. 
   
   
       15 . Method according to  claim 3 , according to which the administration of the oxime and the agent that blocks the OCT is sequential, simultaneous or successive; preferably the administration of the agent that blocks the OCT is done before the administration of the oxime. 
   
   
       16 . Method according to  claim 2 , according to which the administration is oral or parenteral. 
   
   
       17 . Pharmaceutical composition according to  claim 10 , where the agent that blocks the OCT is selected from the group that comprises tetraethylammonium (TEA), thiamine, and mixtures thereof. 
   
   
       18 . Pharmaceutical composition according to  claim 10 , wherein the oxime is pralidoxime or one of its pharmaceutically acceptable salts, such as methyl sulfate, and the agent that blocks the OCT is tetraethylammonium (TEA).